Highline Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Highline Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-56,304	Closed	-$765K	–	20
2020 Q1	$765K	Buy	56,304 +24,900	+79%	+$319K	0.19%	24
2019 Q4	$341K	Sell	31,404 -57,962	-65%	-$607K	0.05%	22
2019 Q3	$918K	Sell	89,366 -128,500	-59%	-$1.39M	0.13%	25
2019 Q2	$2.06M	Buy	217,866 +170,152	+357%	+$1.25M	0.15%	32
2019 Q1	$326K	Buy	+47,714	New	+$244K	0.02%	34

Other funds holding ARCT

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Highline Capital Management's ARCT Position: Q2 2020 in Review

Highline Capital Management sold out of Arcturus Therapeutics (ARCT) in Q2 2020, closing a stake of 56,304 shares — an estimated $765K sold.

Highline Capital Management first reported a position in ARCT in Q1 2019 and held it in 5 quarters. The position peaked at $2.06M in Q2 2019. 114 funds tracked by Wall St. Rank hold ARCT as of Q2 2020.

Highline Capital Management reported no remaining Arcturus Therapeutics position as of Q2 2020 after selling out during the quarter.
Highline Capital Management sold 56,304 Arcturus Therapeutics shares in Q2 2020, an estimated $765K.
Highline Capital Management first reported a position in Arcturus Therapeutics in Q1 2019 and held it in 5 quarters.
Highline Capital Management's Arcturus Therapeutics position peaked at $2.06M in Q2 2019.
114 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2020.

Based on Highline Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.